Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neoadjuvant chemotherapy for patients with locally advanced vulvar cancer

Neoadjuvant chemotherapy for patients with locally advanced vulvar cancer Purpose of reviewStudies on treatment options for patients with locally advanced vulvar cancer (LAVC) are scarce, and high-level evidence for a primary treatment choice is lacking. Furthermore, current treatment options are associated with extensive morbidity and high complication rates. More effective treatment options are urgently needed. This review describes current treatment possibilities, focusing on literature regarding neoadjuvant chemotherapy (NACT) followed by surgery.Recent findingsAlthough data are heterogeneous and limited, NACT followed by surgery might be an effective and well tolerated treatment alternative associated with lower morbidity compared with current treatment options, such as excenterative surgery or definitive chemoradiation.SummaryUp until now, several studies describe an overall response rate of 40–86%. Surgery turned out to be possible in 40–90% of the LAVC patients who received NACT. Prospective studies on the efficacy and safety of NACT followed by surgery with a homogeneous chemotherapy regimen are urgently awaited. NACT should, at this point, still be considered investigational. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Oncology Wolters Kluwer Health

Neoadjuvant chemotherapy for patients with locally advanced vulvar cancer

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/neoadjuvant-chemotherapy-for-patients-with-locally-advanced-vulvar-B4rRf03sfB

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1040-8746
eISSN
1531-703X
DOI
10.1097/cco.0000000000000861
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewStudies on treatment options for patients with locally advanced vulvar cancer (LAVC) are scarce, and high-level evidence for a primary treatment choice is lacking. Furthermore, current treatment options are associated with extensive morbidity and high complication rates. More effective treatment options are urgently needed. This review describes current treatment possibilities, focusing on literature regarding neoadjuvant chemotherapy (NACT) followed by surgery.Recent findingsAlthough data are heterogeneous and limited, NACT followed by surgery might be an effective and well tolerated treatment alternative associated with lower morbidity compared with current treatment options, such as excenterative surgery or definitive chemoradiation.SummaryUp until now, several studies describe an overall response rate of 40–86%. Surgery turned out to be possible in 40–90% of the LAVC patients who received NACT. Prospective studies on the efficacy and safety of NACT followed by surgery with a homogeneous chemotherapy regimen are urgently awaited. NACT should, at this point, still be considered investigational.

Journal

Current Opinion in Oncology – Wolters Kluwer Health

Published: Sep 5, 2022

References

  • Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma
  • Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways
  • Role of chemotherapy in vulvar cancers: time to rethink standard of care?
  • Vulvar cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
  • Cancer of the vulva
  • New FIGO staging system of vulvar cancer indeed provides a better reflection of prognosis
  • Surgery and radiotherapy in vulvar cancer
  • Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer
  • Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study
  • The radiotherapy role in the multidisciplinary management of locally advanced vulvar cancer: a multidisciplinary VulCan Team Review
  • Systemic treatment of vulvar cancer
  • Locally advanced squamous cell carcinoma of the vulva: a challenging question for gynecologic oncologists
  • Unresectable’ vulval cancers: is neoadjuvant chemotherapy the way forward?
  • Clinical analysis of neoadjuvant chemotherapy in patients with advanced vulvar cancer: a STROBE-compliant article
  • Performance and outcome of pelvic exenteration for gynecologic malignancies: a population-based study
  • Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan
  • High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: outcome and toxicity
  • Primary versus preoperative radiation for locally advanced vulvar cancer
  • Chemoradiation for advanced primary vulval cancer
  • Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse
  • A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study
  • Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva
  • Preoperative chemoradiation for locally advanced carcinoma of the vulva
  • Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study
  • Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group
  • Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer
  • Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study
  • Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma
  • Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva
  • Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva
  • Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva
  • Concurrent radiation and chemotherapy in vulvar carcinoma
  • Treatment of inoperable vulvar cancer: where we come from and where are we going
  • Neoadjuvant chemoradiation for advanced primary vulvar cancer
  • Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: an efficacy study
  • Risk factors and treatment for recurrent vulvar squamous cell carcinoma
  • Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
  • A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
  • Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
  • Dose-dense paclitaxel- and carboplatin-based neoadjuvant chemotherapy followed by surgery or concurrent chemo-radiotherapy in cervical cancer: a preliminary analysis
  • Neoadjuvant chemotherapy in patients with advanced endometrial cancer
  • Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience
  • Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: time to rethink standard of care?
  • Neoadjuvant chemotherapy in advanced vulvar cancer
  • Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva
  • Brief report on 3-weekly paclitaxel carboplatin efficacy in locally advanced or metastatic squamous vulvar cancer
  • Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer
  • Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature
  • Genomic characterization of vulvar (pre)cancers identifies distinct molecular subtypes with prognostic significance
  • Targeted therapeutic approaches in vulvar squamous cell cancer (VSCC): case series and review of the literature
  • Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
  • Pembrolizumab in recurrent squamous cell carcinoma of the vulva: case report and review of the literature
  • A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
  • Use of electrochemotherapy in women with vulvar cancer to improve quality-of-life in the palliative setting: a meta-analysis